Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE BioTrends Research Group
Surveyed Oncologists Indicate Kadcyla is the Patient Share Leader for Second-Line HER2-Positive, HR-Negative Breast Cancer, According to a New Report from BioTrends Research Group
EXTON, Pa., Dec. 19, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, according to oncologists surveyed in Q4 2013, Roche/Genentech's Perjeta in combination with Roche/Genentech's Herceptin and docetaxel is prescribed to over one-third of first-line HER2-positive, hormone-receptor (HR)-negative advanced/metastatic breast cancer patients. Findings in the same HER2-positive, HR-negative population reveal that Roche/Genentech's Kadcyla has become the patient-share leader in the second-line setting. Surveyed oncologists also reported that Novartis's Afinitor holds modest patient shares in the second- and third-line settings for HR-positive, HER2-negative breast cancer.
The TreatmentTrends® Advanced/Metastatic Breast Cancer (US) Q3 2013 report, in which 100 medical oncologists were surveyed about their current and expected treatment practices for breast cancer, also finds that out-of-pocket costs to patients is one of the top three main obstacles that prevent surveyed physicians from prescribing currently available premium-priced treatments for advanced/metastatic breast cancer. Notably, other key obstacles to prescribing were safety/tolerability and managed care/prior authorization problems.
"The market entry of several novel targeted agents with strong efficacy data in the last 18 months is changing previous treatment paradigms," said Decision Resources Group Principal Business Insights Analyst Amy Duval, M.Res. "These new market entries command premium prices, and some cost-related issues are obstacles to prescribing for surveyed oncologists."
TreatmentTrends® Advanced/Metastatic Breast Cancer is a syndicated report designed to provide a view of the current and future management of breast cancer based on primary research fielded with 100 medical oncologists in the United States. The report evaluates treatment and diagnosis patterns of the disease and physician opinions on possible future therapy options. BioTrends Oncology is also covering the launch of Perjeta and Kadcyla through its LaunchTrends® studies.
About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.